Nexalin plans to submit a Q-Submission to the FDA for its Gen-2 SYNC system targeting Alzheimer's and cognitive impairments. Nexalin Technology, Inc. announced its intention to submit a Q-Submission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback